TABLE 2.
Cardiac structure and function and intravascular volumes before (pre-) and after (post-) 6 weeks of twice-daily administration of formoterol (48 µg·day−1) or placebo in endurance-trained participants (19 males, one female)
| Formoterol | Placebo | Formoterol versus placebo effect size mean change (95% CI) | Interaction p-value | |||
| Pre | Post | Pre | Post | |||
| Participants | 10 | 10 | ||||
| Cardiac parameters | ||||||
| LV mass (g) | 226±52 | 233±45 | 225±32 | 224±27 | 8 (−3 to 20) | 0.158 |
| LV mass index (g·m−2) | 115±25 | 118±22 | 115±15 | 115±11 | 4 (−2 to 10) | 0.154 |
| Total haemoglobin mass and intravascular volumes | ||||||
| Blood volume (L) | 6.2±0.6 | 6.3±0.8 | 6.3±0.6 | 6.3±0.4 | 0.1 (−0.4 to 0.4) | 0.796 |
| Plasma volume (L) | 3.7±0.4 | 3.6±0.5 | 3.6±0.5 | 3.6±0.3 | 0.1 (−0.4 to 0.3) | 0.792 |
| Total haemoglobin mass (g) | 897±128 | 904±135 | 897±76 | 897±76 | 7 (−24 to 39) | 0.631 |
Data are presented as n or mean±sd, unless otherwise stated. LV: left ventricle.